Live Science on MSN
'This is a completely different level of anti-vaccine engagement than we've ever seen before,' says epidemiologist Dr. Seth Berkley
Epidemiologist Dr. Seth Berkley spoke to Live Science about the importance of vaccine equity and the obstacles undermining it ...
Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing ...
Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...
The vaccine, known as mRNA-1647, showed disappointing efficacy against primary CMV infection in healthy women, ranging from ...
Robert Dowd, CSC, during which McElroy offered his thoughts on ways to address political polarization in America. The event ...
Topline results were announced from a phase 3 study evaluating Moderna’s cytomegalovirus vaccine candidate, mRNA-1647.
This insightful review explores key areas of cancer genetic research, focusing on genes that may benefit from ...
US biotech Moderna (Nasdaq: MRNA) is discontinuing its once-promising vaccine for congenital cytomegalovirus (CMV) after the shot failed to prevent primary infection in healthy women during a Phase ...
The Brighterside of News on MSN
Flatworms defy stem cell rules, offering a blueprint for human regeneration
A team of scientists has mapped the regions surrounding stem cells in planarians—small flatworms that are famous for being able to regrow whole bodies from small fragments—and discovered something ...
Investor's Business Daily on MSN
Moderna Topples, Threatening Its 50-Day Line, After A Key Vaccine Bites The Dust
Moderna stock toppled Thursday after the biotech company's experimental CMV vaccine failed in a Phase 3 study of 7,500 women.
Q3 2025 Earnings Call October 24, 2025 8:30 AM EDTCompany ParticipantsThomas Larsen - Head of Investor RelationsPaul Hudson - CEO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback